Khawcharoenporn Thana, Vasoo Shawn, Singh Kamaljit
Division of Infectious Diseases, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand ; Section of Infectious Diseases, Rush University Medical Center, Chicago, IL 60612, USA.
Emerg Med Int. 2013;2013:258517. doi: 10.1155/2013/258517. Epub 2013 Oct 31.
Background. Selection of empiric antibiotics for urinary tract infections (UTIs) has become more challenging because of the increasing rates of multidrug-resistant Enterobacteriaceae (MDRE) infections. Methods. This retrospective study was conducted to determine antibiotic resistance patterns, risk factors, and appropriate empiric antibiotic selection for MDRE UTIs. Adult patients seen in the Emergency Department (ED) with Enterobacteriaceae UTIs during 2008-2009 were identified from review of microbiology records. MDRE were defined as organisms resistant to at least 3 categories of antibiotics. Results. There were 431 eligible patients; 83 (19%) had MDRE UTIs. Resistance rates for individual antibiotics among MDRE UTIs were significantly greater than non-MDRE UTIs: levofloxacin, 72% versus 14%; TMP-SMX, 77% versus 12%; amoxicillin-clavulanate, 35% versus 4%; nitrofurantoin, 21% versus 12%, and ceftriaxone, 20% versus 0%. All Enterobacteriaceae isolates were susceptible to ertapenem (MIC ≤ 2 mg/L). Independent risk factors for MDRE UTI were prior fluoroquinolone use within 3 months (adjusted odds ratio (aOR) 3.64; P = 0.001), healthcare-associated risks (aOR 2.32; P = 0.009), and obstructive uropathy (aOR 2.22; P = 0.04). Conclusion. Our study suggests that once-daily intravenous or intramuscular ertapenem may be appropriate for outpatient treatment of ED patients with MDRE UTI.
背景。由于多重耐药肠杆菌科(MDRE)感染率不断上升,选择用于治疗尿路感染(UTI)的经验性抗生素变得更具挑战性。方法。开展这项回顾性研究以确定MDRE所致UTI的抗生素耐药模式、危险因素及合适的经验性抗生素选择。通过查阅微生物学记录,确定了2008 - 2009年期间在急诊科(ED)就诊的患有肠杆菌科UTI的成年患者。MDRE被定义为对至少3类抗生素耐药的微生物。结果。有431例符合条件的患者;83例(19%)患有MDRE所致UTI。MDRE所致UTI中各抗生素的耐药率显著高于非MDRE所致UTI:左氧氟沙星,72%对14%;复方新诺明,77%对12%;阿莫西林 - 克拉维酸,35%对4%;呋喃妥因,21%对12%;头孢曲松,20%对0%。所有肠杆菌科分离株对厄他培南敏感(MIC≤2mg/L)。MDRE所致UTI的独立危险因素为3个月内曾使用氟喹诺酮类药物(校正比值比(aOR)3.64;P = 0.001)、医疗相关风险(aOR 2.32;P = 0.009)和梗阻性尿路病(aOR 2.22;P = 0.04)。结论。我们的研究表明,每日1次静脉或肌内注射厄他培南可能适用于门诊治疗ED中患有MDRE所致UTI的患者。